Research Article
Investigation of the Definition of De Novo Oligometastatic Nasopharyngeal Carcinoma: A Retrospective Study
Table 1
The clinical baseline data and univariate survival analysis of 191 patients.
| Factor | Cases (%) | Median OS (month) | HR (95% CI) | value |
| Sex | Male | 153 (80.1) | 41.8 | | 0.563 | Female | 38 (19.9) | 35.7 | 1.13 (0.75–1.72) | |
| Age | ≤49 | 102 (53.4) | 41.2 | | 0.853 | >49 | 89 (46.6) | 41.1 | 1.03 (0.74–1.45) | |
| Pathological type | WHO type I/II | 14 (7.3) | 41.4 | | 0.198 | WHO type III | 177 (92.7) | 19.2 | 1.46 (0.82–2.59) | |
| KPS | <80 | 50 (26.2) | 15.9 | | <0.001 | ≥80 | 141 (73.8) | 48.8 | 0.35 (0.24–0.51) | |
| T stage | 1-2 | 38 (19.9) | 51.9 | | 0.440 | 3-4 | 153 (80.1) | 34.0 | 1.19 (0.77–1.84) | |
| N stage | 0-1 | 27 (14.1) | 64.7 | | 0.007 | 2-3 | 164 (85.9) | 36.4 | 2.07 (1.21–3.57) | |
| Number of metastatic organs | Single | 126 (66.0) | 51.2 | | <0.001 | Multiple | 65 (34.0) | 18.9 | 2.41 (1.69–3.45) | |
| Number of metastases | 1–3 | 61 (31.9) | 68.5 | | | 4-5 | 33 (17.3) | 53.7 | 1.40 (0.80–2.43) | 0.244 | >5 | 97 (50.8) | 17.9 | 4.37 (2.79–6.86) | <0.001 |
| Bone metastasis | Yes | 124 (64.9) | 43.2 | | 0.747 | No | 67 (35.1) | 28.5 | 0.94 (0.66–1.35) | |
| Lung metastasis | Yes | 52 (27.2) | 23.7 | | 0.026 | No | 139 (72.8) | 45.7 | 0.66 (0.45–0.95) | |
| Liver metastasis | Yes | 70 (36.6) | 20.7 | | <0.001 | No | 121 (63.4) | 50.4 | 0.49 (0.35–0.70) | |
| Nasopharyngeal radiotherapy | Yes | 149 (78.0) | 47.4 | | <0.001 | No | 42 (22.0) | 16.1 | 2.80 (1.89–4.14) | |
| Dose at primary tumor | <70 Gy | 25 (16.8) | 18.4 | | <0.001 | ≥70 Gy | 124 (83.2) | 51.1 | 0.38 (0.23–0.63) | |
| Platinum-containing chemotherapy | Doublet | 128 (69.6) | 39.4 | | 0.162 | Triplet | 56 (30.4) | 39.6 | 0.76 (0.51–1.12) | |
| Cycles of first-line chemotherapy | <6 | 124 (64.9) | 37.3 | | 0.045 | ≥6 | 67 (35.1) | 48.2 | 0.69 (0.48–0.99) | |
| Metastasis treatment | Yes | 44 (23.0) | 29.9 | | 0.552 | No | 147 (77.0) | 43.7 | 0.89 (0.61–1.31) | |
|
|